H.R. 3583 (109th): Protecting Free Trade in Pharmaceuticals Act of 2005

Jul 28, 2005 (109th Congress, 2005–2006)
Died (Referred to Committee)
Anne Northup
Representative for Kentucky's 3rd congressional district
Read Text »
Last Updated
Jul 28, 2005
4 pages
Related Bills
S. 1551 (identical)

Referred to Committee
Last Action: Jul 28, 2005


This bill was introduced on July 28, 2005, in a previous session of Congress, but was not enacted.

Introduced Jul 28, 2005
Referred to Committee Jul 28, 2005
Full Title

To clarify that the overall trade negotiating objectives of the United States include avoiding provisions in trade agreements that restrict the access of consumers in the United States to pharmaceutical imports, and for other purposes.


No summaries available.

Primary Source

THOMAS.gov (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here. Data comes via the congress project.


Get a bill status widget for your website »


Click a format for a citation suggestion:


H.R. stands for House of Representatives bill.

A bill must be passed by both the House and Senate in identical form and then be signed by the president to become law.

The bill’s title was written by its sponsor.

GovTrack’s Bill Summary

We don’t have a summary available yet.

Library of Congress Summary

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.

Protecting Free Trade in Pharmaceuticals Act of 2005 - Amends the Bipartisan Trade Promotion Authority Act of 2002 to include among the overall trade negotiating objectives of the United States avoiding negotiating trade agreements that could restrict, or be interpreted to restrict, the access of consumers in the United States to pharmaceutical imports from countries with a pharmaceutical infrastructure that is equivalent, or superior, to that of the United States:
(1) by or through the use and development of the doctrine of international patent exhaustion, as interpreted or applied by U.S. courts on the enactment of this Act; or
(2) by making it a violation for the United States to enact legislation permitting pharmaceutical imports without the consent of patent owners when the products involved have been sold outside the United States.
Prohibits the U.S. Trade Representative (USTR) from:
(1) entering into a bilateral or multilateral trade agreement that, with respect to the importation of pharmaceutical products without the consent of the patent owners, includes provisions identical or similar to the provisions of the United States-Singapore Free Trade Agreement, the United States-Australia Free Trade Agreement, or the United States-Morocco Free Trade Agreement; or
(2) negotiating an agreement or understanding with respect to any of such provisions.
Requires the USTR, with respect to the advisory committee on matters relating to intellectual property, to ensure that, for each meeting that relates or potentially relates to the importation of pharmaceutical products into the United States, at least 10% of the committee members represent the interests of consumers of such products.

House Republican Conference Summary

The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.

No summary available.

House Democratic Caucus Summary

The House Democratic Caucus does not provide summaries of bills.

So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.

We’ll be looking for a source of summaries from the other side in the meanwhile.

Use the comment space below for discussion of the merits of H.R. 3583 (109th) with other GovTrack users.
Your comments are not read by Congressional staff.

comments powered by Disqus